ARTICLE | Clinical News

BerGenBio starts Phase II of BGB324 to treat TNBC

November 17, 2017 7:58 PM UTC

BerGenBio ASA (OSE:BGBIO) began a Phase II trial evaluating BGB324 in combination with Keytruda pembrolizumab in up to 56 patients with previously treated, locally advanced or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC).

The open-label, international trial's primary endpoint is objective response rate (ORR). Secondary endpoints include disease control rate (DCR), duration of response, time to progression, overall survival (OS) and safety...

BCIQ Company Profiles

BerGenBio ASA